Sunil Daniel1, Taraneh Soleymani, W Timothy Garvey. 1. Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham VA Medical Center, Birmingham, AL 35294-3360, USA. sunild@uab.edu
Abstract
PURPOSE OF REVIEW: The current medical model for obesity management is BMI-centric because BMI is the predominant measure used to gauge disease severity, as well as indications for various treatment modalities. Recent advancements in therapy and understanding of the relationship between BMI and obesity-related complications call for a re-examination of this approach. RECENT FINDINGS: Advancements in treatment, including the recent approval of two new weight loss medications in the USA, have enabled development of new medical models for management of obesity. On the basis of accumulating data demonstrating the benefits of weight loss regarding multiple obesity-related complications (e.g., diabetes prevention, type 2 diabetes mellitus, cardiovascular disease risk, nonalcoholic steatohepatitis, sleep apnea), a complications-centric model is proposed that employs weight loss as a tool to treat and prevent obesity comorbidities. This model assures that the aggressiveness of therapy is commensurate with disease severity, and that therapy is directed at those obese patients who will benefit most from weight loss therapy. The treatment algorithm is comprehensive in addressing complications and quantitative when possible in the staging of risk or disease severity. SUMMARY: A complications-centric approach to obesity management identifies patients who will benefit most from weight loss, and optimizes patient outcomes, benefit/risk ratio, and the cost-effectiveness of interventions.
PURPOSE OF REVIEW: The current medical model for obesity management is BMI-centric because BMI is the predominant measure used to gauge disease severity, as well as indications for various treatment modalities. Recent advancements in therapy and understanding of the relationship between BMI and obesity-related complications call for a re-examination of this approach. RECENT FINDINGS: Advancements in treatment, including the recent approval of two new weight loss medications in the USA, have enabled development of new medical models for management of obesity. On the basis of accumulating data demonstrating the benefits of weight loss regarding multiple obesity-related complications (e.g., diabetes prevention, type 2 diabetes mellitus, cardiovascular disease risk, nonalcoholic steatohepatitis, sleep apnea), a complications-centric model is proposed that employs weight loss as a tool to treat and prevent obesity comorbidities. This model assures that the aggressiveness of therapy is commensurate with disease severity, and that therapy is directed at those obesepatients who will benefit most from weight loss therapy. The treatment algorithm is comprehensive in addressing complications and quantitative when possible in the staging of risk or disease severity. SUMMARY: A complications-centric approach to obesity management identifies patients who will benefit most from weight loss, and optimizes patient outcomes, benefit/risk ratio, and the cost-effectiveness of interventions.
Authors: Samuel Klein; Lora E Burke; George A Bray; Steven Blair; David B Allison; Xavier Pi-Sunyer; Yuling Hong; Robert H Eckel Journal: Circulation Date: 2004-10-27 Impact factor: 29.690
Authors: Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs Journal: Hepatology Date: 2004-12 Impact factor: 17.425
Authors: M Sullivan; J Karlsson; L Sjöström; L Backman; C Bengtsson; C Bouchard; S Dahlgren; E Jonsson; B Larsson; S Lindstedt Journal: Int J Obes Relat Metab Disord Date: 1993-09
Authors: M G Grammatikopoulou; M Chourdakis; K Gkiouras; P Roumeli; D Poulimeneas; E Apostolidou; I Chountalas; I Tirodimos; O Filippou; S Papadakou-Lagogianni; T Dardavessis Journal: J Endocrinol Invest Date: 2018-01-08 Impact factor: 4.256
Authors: Marvin Ryou; Kenneth R McQuaid; Christopher C Thompson; Steven Edmundowicz; Klaus Mergener Journal: Surg Endosc Date: 2017-11-14 Impact factor: 4.584
Authors: Marvin Ryou; Kenneth R McQuaid; Christopher C Thompson; Steven Edmundowicz; Klaus Mergener Journal: Obes Surg Date: 2018-01 Impact factor: 4.129
Authors: Marvin Ryou; Kenneth R McQuaid; Christopher C Thompson; Steven Edmundowic; Klaus Mergener Journal: J Gastrointest Surg Date: 2017-11-14 Impact factor: 3.452
Authors: Charles M Yarborough; Stacy Brethauer; Wayne N Burton; Raymond J Fabius; Pamela Hymel; Shanu Kothari; Robert F Kushner; John Magaña Morton; Kathryn Mueller; Nicolaas P Pronk; Mitchell S Roslin; David B Sarwer; Brian Svazas; Jeffrey S Harris; Garrett I Ash; Jamie T Stark; Marianne Dreger; Julie Ording Journal: J Occup Environ Med Date: 2018-01 Impact factor: 2.162
Authors: Amarpreet S Chawla; Chia-Wen Hsiao; Martha C Romney; Ricardo Cohen; Francesco Rubino; Philip Schauer; Pierre Cremieux Journal: Pharmacoeconomics Date: 2015-07 Impact factor: 4.981